Aridis Pharmaceuticals Respiratory Health Investor Presentation 2021

Aridis Pharmaceuticals presents its pipeline of innovative monoclonal antibody and immunotherapy candidates for treating respiratory infections and related conditions. The presentation outlines preclinical and clinical-stage programs targeting gram-positive and gram-negative bacteria, including therapies for pneumonia, cystic fibrosis, and COVID-19.